EGFR
E902872
cell surface receptor
human gene
proto-oncogene protein
receptor tyrosine kinase
transmembrane protein
EGFR (epidermal growth factor receptor) is a transmembrane receptor tyrosine kinase that regulates cell growth and survival and is frequently implicated in cancer development and progression.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| EGFR (ERBB1) | 1 |
Statements (78)
| Predicate | Object |
|---|---|
| instanceOf |
cell surface receptor
ⓘ
human gene ⓘ proto-oncogene protein ⓘ receptor tyrosine kinase ⓘ transmembrane protein ⓘ |
| activatedBy |
amphiregulin
NERFINISHED
ⓘ
betacellulin NERFINISHED ⓘ epidermal growth factor NERFINISHED ⓘ epigen ⓘ epiregulin NERFINISHED ⓘ heparin-binding EGF-like growth factor ⓘ transforming growth factor alpha NERFINISHED ⓘ |
| alsoKnownAs |
ERBB1
NERFINISHED
ⓘ
HER1 NERFINISHED ⓘ epidermal growth factor receptor tyrosine kinase NERFINISHED ⓘ |
| associatedWithDisease |
breast cancer
ⓘ
colorectal cancer ⓘ glioblastoma ⓘ head and neck squamous cell carcinoma ⓘ non-small cell lung cancer ⓘ |
| belongsToFamily | ErbB receptor family NERFINISHED ⓘ |
| biologicalProcess |
apoptotic process regulation
ⓘ
cell differentiation ⓘ regulation of cell proliferation ⓘ regulation of cell survival ⓘ signal transduction ⓘ |
| cellularComponent |
cell surface
ⓘ
endosome ⓘ plasma membrane ⓘ |
| downstreamPathway |
JAK-STAT signaling pathway
NERFINISHED
ⓘ
PI3K-AKT signaling pathway NERFINISHED ⓘ PLCγ-PKC signaling pathway ⓘ RAS-RAF-MEK-ERK signaling pathway NERFINISHED ⓘ |
| encodes | epidermal growth factor receptor protein NERFINISHED ⓘ |
| endocytosis | clathrin-mediated internalization after activation ⓘ |
| fullName | epidermal growth factor receptor NERFINISHED ⓘ |
| geneSymbol | EGFR NERFINISHED ⓘ |
| hasDomain |
extracellular ligand-binding domain
ⓘ
intracellular tyrosine kinase domain ⓘ single-pass transmembrane domain ⓘ |
| hasEntrezGeneID | 1956 ⓘ |
| hasHGNCID | HGNC:3236 ⓘ |
| hasLength | 1210 amino acids (canonical human isoform) ⓘ |
| hasUniProtID | P00533 ⓘ |
| involvedIn |
cancer development
ⓘ
cancer progression ⓘ |
| locatedAtCytogeneticBand | 7p11.2 GENERATED ⓘ |
| locatedOnChromosome | human chromosome 7 ⓘ |
| locatedOnChromosomeArm | 7p ⓘ |
| mechanismOfActivation |
autophosphorylation of tyrosine residues
ⓘ
ligand-induced receptor dimerization ⓘ |
| molecularFunction |
ATP binding
ⓘ
protein tyrosine kinase activity ⓘ transmembrane receptor activity ⓘ |
| oncogenicAlteration |
EGFRvIII deletion mutant
NERFINISHED
ⓘ
L858R point mutation in exon 21 ⓘ T790M resistance mutation ⓘ activating point mutation ⓘ exon 19 deletion mutation ⓘ extracellular domain mutation ⓘ gene amplification ⓘ |
| organism | Homo sapiens ⓘ |
| postTranslationalModification |
N-linked glycosylation
ⓘ
tyrosine phosphorylation ⓘ |
| recyclingOrDegradation | sorted to lysosomal degradation or recycled to plasma membrane ⓘ |
| regulates |
angiogenesis-related signaling
ⓘ
cell cycle progression ⓘ cell migration ⓘ |
| targetOfDrug |
afatinib
NERFINISHED
ⓘ
cetuximab ⓘ dacomitinib NERFINISHED ⓘ erlotinib NERFINISHED ⓘ gefitinib NERFINISHED ⓘ necitumumab NERFINISHED ⓘ osimertinib NERFINISHED ⓘ panitumumab NERFINISHED ⓘ |
| targetOfDrugClass |
EGFR tyrosine kinase inhibitors
ⓘ
anti-EGFR monoclonal antibodies ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
EGFR (ERBB1)